BCM
NPCE icon

Bridgeway Capital Management’s Neuropace NPCE Stock Holding History

Bridgeway Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,400
Closed -$374K – 1231
2025
Q1 		$374K Hold
30,400
– – 0.01% 799
2024
Q4 		$340K Sell
30,400
-2,800
-8% -$24.3K 0.01% 897
2024
Q3 		$231K Hold
33,200
– – 0.01% 1029
2024
Q2 		$251K Hold
33,200
– – 0.01% 1000
2024
Q1 		$438K Sell
33,200
-700
-2% -$9.98K 0.01% 953
2023
Q4 		$350K Sell
33,900
-26,148
-44% -$209K 0.01% 1035
2023
Q3 		$584K Hold
60,048
– – 0.01% 839
2023
Q2 		$270K Buy
60,048
+8,400
+16% +$38K 0.01% 1069
2023
Q1 		$240K Buy
51,648
+20,000
+63% +$76.6K 0.01% 1070
2022
Q4 		$47.2K Hold
31,648
– – ﹤0.01% 1303
2022
Q3 		$119K Buy
31,648
+5,500
+21% +$26.5K ﹤0.01% 1246
2022
Q2 		$129K Buy
+26,148
New +$173K ﹤0.01% 1178

Other funds holding NPCE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return

Bridgeway Capital Management's NPCE Position: Q2 2025 in Review

Bridgeway Capital Management sold out of Neuropace (NPCE) in Q2 2025, closing a stake of 30,400 shares — an estimated $374K sold.

Bridgeway Capital Management first reported a position in NPCE in Q2 2022 and held it in 12 quarters. The position peaked at $584K in Q3 2023. 98 funds tracked by Wall St. Rank hold NPCE as of Q2 2025.

  • Bridgeway Capital Management reported no remaining Neuropace position as of Q2 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 30,400 Neuropace shares in Q2 2025, an estimated $374K.
  • Bridgeway Capital Management first reported a position in Neuropace in Q2 2022 and held it in 12 quarters.
  • Bridgeway Capital Management's Neuropace position peaked at $584K in Q3 2023.
  • 98 funds tracked by Wall St. Rank held Neuropace as of Q2 2025.

Based on Bridgeway Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.